• Home
  • NEW DAY MEDICINE
  • 8 (70) 2024
  • 64 -8 (70) 2024 - Atoeva M.N. - THE ROLE OF LABORATORY BIOCHEMICAL PARAMETERS OF THE LIVER IN THE DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE

64 -8 (70) 2024 - Atoeva M.N. - THE ROLE OF LABORATORY BIOCHEMICAL PARAMETERS OF THE LIVER IN THE DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE

THE ROLE OF LABORATORY BIOCHEMICAL PARAMETERS OF THE LIVER IN THE DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE

Atoeva M.N. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The results of the biochemical blood test indicate the presence of dyslipidemia and an increase in glycemia levels relative to the control group in patients with nonalcoholic steatosis. The identified changes should be taken into account when determining the therapeutic tactics in patients with NAFLD.

Key words: non-alcoholic fatty liver disease, obesity, diabetes mellitus, metabolic dysfunction¬, atherogenic dyslipidemia, fatty degeneration, α-2-macroglobulin, haptoglobin, cytolysis, cholestasis, nonalcoholic steatosis.

First page

355

Last page

360

For citation:Atoeva M.N. - THE ROLE OF LABORATORY BIOCHEMICAL PARAMETERS OF THE LIVER IN THE DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE //New Day in Medicine 8(70)2024 355-360 https://newdayworldmedicine.com/en/new_day_medicine/8-70-2024

List of References

  1. Евстифеева С.Е., Шальнова С.А., Куценко В.А. и др. Распространенность неал-когольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилак¬тика. 2022;21(9):3356. [Evstifeeva S.E., Shalnova S.A., Kutsenko V.A. et al. Prevalence of non-alcoholic fatty liver disease in the working-age population: association with socio-demographic indicators and behavioral risk factors (data from ESSE-RF-2). Cardiovascular therapy and prevention. 2022;21(9):3356 (in Russ.)]. DOI: 10.15829/1728-8800-2022-3356.
  2. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. //РЖГГК. 2016;2:24-42.
  3. Ткач С. М. Современная фармакотерапия неалкогольной жировой болезни печени / С. М. Ткач, Т. Ю. Юзвенко, Т. Л. Чеверда //Здоров’я України. 2017;18:68-71.
  4. Маев И.В., Андреев Д.Н., Кучерявый Ю.А. [и др.] Неалкогольная жировая болезнь печени с позиции современной медицины. /М., 2020; 7-35 стр.
  5. Драпкина О.М., Буеверов А. О. Неалкогольная жировая болезнь печени как мультидисциплинарная патология. М.: Видокс, 2017, 104 с. Drapkina O. M., Bueverov A. O. Nealkogol’naya zhirovaya bolezn’ pecheni kak mul’tidistciplinarnaya patologiya [Non-alcoholic fatty liver disease as a multidisciplinary pathology]. M.: Vidoks, 2017, 104 p.
  6. Younossi Z.M., Koenig A. B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease – Metaanalytic assessment of prevalence, incidence, and outcomes. //Hepatology, 2016;64(1):73-84.
  7. Диагностика и лечение неалкогольной жировой болезни печени: методические рекомендации для врачей Российского общества по изучению печени. М.: МЕДпресс-информ, 2015, 48 c. Diagnostika i leceniye nealkogol’noi zhirovoi bolezni pecheni: metodicheskiye recommendatcii dlya vrachey Rossiiskogo obshestva po izucheniyu pecheni [Diagnosis and treatment of non-alcoholic fatty liver disease: guidelines for doctors of the Russian society for the study of the liver]. M.: MEDpress-inform, 2015, 48 p.
  8. Ye J, Wu Y, Li F, Wu T, Shao C, Lin Y, Wang W, Feng S, Zhong B. Eff ect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. //Th erapeutic Advances in Gastroenterology. 2019;(12):1-16. DOI: 10.1177/175628481987 9047
  9. Wang H, Wang L, Cheng Y, Xia Z, Liao Y, Cao J. Effi cacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis. //Biological and Biomedical Reports. 2018;9(1):90-96. DOI: 10.3892/ br.2018.1100
  10. Ranjbar G, Mikhailidis DP, Sahebkar A. Eff ects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Th ink out of the box! //Metabolism. 2019;(101):154001. DOI: 10.1016/j.metabol.2019.154001
  11. Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. //Current Obesity Reports. 2019;8(2):156-164. DOI: 10.1007/s13679-019- 00335-3
  12. Zhou J, Massey S, Story D, Li L. Metformin: An Old Drug with New Applications. //International Journal of Molecular Medical Science. 2018;(21):E2863. DOI: 10.3390/ ijms191028630
  13. Von Schönfels W, Beckmann JH, Ahrens M, Hendricks A, Röcken C, Szymczak S, Hampe J, Schafmayer C. Histologic improvement of NAFLD in patients with obesity aft er bariatric surgery based on standardized NAS (NAFLD activity score). Surgery for Obesity and Related Diseases. 2018;(14):1607–16. DOI: 10.1016/j. soard.2018.07.012
  14. Seghieri M, Christensen AS, Andersen A, Solini A, Knop FK, Vilsbøll T. Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. //Frontiers in Endocrinology. 2018;(9):649. DOI:10.3389/fendo.2018.00649
  15. Newsome P Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A. Eff ect of semaglutide on liver enzymes and markers of infl ammation in subjects with type 2 diabetes and/or obesity. //Alimentary Pharmacology and Th erapeutics. 2019;50(2):193-203. DOI:10.1111/apt.15316

    file

    download